Silexion: SIL204 shows multi-mechanism immune sensitization in KRAS-driven cancers

Silexion Therapeutics Corp

SIL204 treatment produced statistically significant upregulation of FAS (death receptor) and downregulation of HLA-G (immune checkpoint) in human KRAS-mutant pancreatic and NSCLC cell lines.
Combined with prior MHC-I upregulation, data supports coordinated immune-sensitization across three key immune pathways.
Findings observed across four distinct KRAS mutations (G12D, G12V, G12C, G12R) in pancreatic and NSCLC models.
Company advancing SIL204 into Phase 2/3; first clinical trial site initiated at Tel Aviv Sourasky Medical Center in July 2026.
Management believes data supports combining SIL204 with anti-PD-(L)1 checkpoint inhibitors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.